D. E. Shaw & Co., Inc. Gilead Sciences, Inc. Call Options Transaction History

D. E. Shaw & Co., Inc.

$107 Billion
Q3 2024

Call Options

21 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$66.59 - $83.99 $8.03 Million - $10.1 Million	120,600 New	120,600 $10.1 Million
Q1 2024 May 15, 2024	BUY	$71.58 - $87.29 $5.94 Million - $7.25 Million	83,000 Added 166.0%	133,000 $9.74 Million
Q4 2023 Feb 14, 2024	SELL	$73.27 - $83.09 $14,654 - $16,618	-200 Reduced 0.4%	50,000 $4.05 Million
Q3 2023 Nov 14, 2023	SELL	$73.94 - $80.67 $1.83 Million - $2 Million	-24,800 Reduced 33.07%	50,200 $3.76 Million
Q2 2023 Aug 14, 2023	SELL	$76.01 - $86.7 $5.7 Million - $6.5 Million	-75,000 Reduced 50.0%	75,000 $5.78 Million
Q1 2023 May 15, 2023	SELL	$77.31 - $88.08 $2.32 Million - $2.64 Million	-30,000 Reduced 16.67%	150,000 $12.4 Million
Q4 2022 Feb 14, 2023	BUY	$62.32 - $89.47 $11.2 Million - $16.1 Million	180,000 New	180,000 $15.5 Million
Q2 2022 Aug 15, 2022	SELL	$57.72 - $65.01 $30.8 Million - $34.7 Million	-533,700 Reduced 89.31%	63,900 $3.95 Million
Q1 2022 May 16, 2022	BUY	$57.92 - $72.58 $25.3 Million - $31.8 Million	437,600 Added 273.5%	597,600 $35.5 Million
Q4 2021 Feb 14, 2022	BUY	$64.88 - $73.64 $5.19 Million - $5.89 Million	80,000 Added 100.0%	160,000 $11.6 Million
Q3 2021 Nov 15, 2021	SELL	$67.69 - $73.03 $17.3 Million - $18.7 Million	-255,600 Reduced 76.16%	80,000 $5.59 Million
Q2 2021 Aug 16, 2021	BUY	$63.47 - $69.35 $16.2 Million - $17.7 Million	255,200 Added 317.41%	335,600 $23.1 Million
Q1 2021 May 17, 2021	SELL	$60.0 - $68.46 $7.35 Million - $8.39 Million	-122,500 Reduced 60.37%	80,400 $5.2 Million
Q4 2020 Feb 16, 2021	BUY	$56.65 - $64.55 $10.6 Million - $12.1 Million	187,200 Added 1192.36%	202,900 $11.8 Million
Q4 2019 Feb 14, 2020	SELL	$61.62 - $67.78 $881,166 - $969,254	-14,300 Reduced 47.67%	15,700 $1.02 Million
Q3 2019 Nov 14, 2019	BUY	$62.51 - $69.0 $1.23 Million - $1.36 Million	19,700 Added 191.26%	30,000 $1.9 Million
Q2 2019 Aug 14, 2019	SELL	$61.87 - $69.38 $1.54 Million - $1.73 Million	-24,900 Reduced 70.74%	10,300 $696,000
Q1 2019 May 15, 2019	SELL	$62.53 - $70.05 $3.36 Million - $3.76 Million	-53,700 Reduced 60.4%	35,200 $2.29 Million
Q4 2018 Feb 14, 2019	SELL	$60.54 - $79.0 $10.8 Million - $14.1 Million	-178,600 Reduced 66.77%	88,900 $5.56 Million
Q3 2018 Nov 14, 2018	BUY	$71.28 - $78.92 $370,656 - $410,384	5,200 Added 1.98%	267,500 $20.7 Million
Q2 2018 Aug 14, 2018	BUY	$64.88 - $75.68 $17 Million - $19.9 Million	262,300 New	262,300 $18.6 Million

Others Institutions Holding GILD

# of Institutions

1,928

Shares Held

992M

Call Options Held

10.5M

Put Options Held

9.75M

Black Rock Inc. New York, NY

121M
Shares

$11 Billion
0.19% of portfolio
Vanguard Group Inc Valley Forge, PA

115M
Shares

$10.5 Billion
0.18% of portfolio
Capital World Investors Los Angeles, CA

76.5M
Shares

$7 Billion
1.03% of portfolio
Capital Research Global Investors Los Angeles, CA

61.8M
Shares

$5.65 Billion
1.12% of portfolio
State Street Corp Boston, MA

60.2M
Shares

$5.5 Billion
0.21% of portfolio

View Full List

About GILEAD SCIENCES, INC.

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $115B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

More about GILD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

News

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.

Account